Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



Benlysta

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Pat Phy Spo Phy	tient's Name: {{MEMFIRST}} {{MEMLAST}} Date: {{TODAY}} tient's ID {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} ysician's Name: {{PHYFIRST}} {{PHYLAST}} ecialty:		
l.	What is the patient's diagnosis? ☐ Active systemic lupus erythematosus (SLE) ☐ Other		
2.	What is the ICD-10 code?		
3.	Will the patient be using the requested drug in combination with other biologics? \square Yes \square No		
1.	Is the patient currently receiving treatment with the requested medication? \square Yes \square No If No, skip to #6		
5.	Has the patient achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition? <i>ACTION REQUIRED: If Yes, attach medical records</i> (e.g., chart notes, lab reports) documenting disease stability or improvement. Yes No No further questions		
5.	Does the patient have severe active central nervous system (CNS) lupus [including seizures that are attributed to CNS lupus, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis requiring therapeutic intervention within 60 days before initiation of belimumab (Benlysta)]?		
7.	Prior to initiating therapy, is the patient positive for autoantibodies relevant to systemic lupus erythematosus (SLE) (e.g., ANA, anti-ds DNA, anti-Sm)? ACTION REQUIRED: If Yes, attach medical records (e.g., chart notes, lab reports) documenting the presence of autoantibodies relevant to SLE (e.g., ANA, anti-ds DNA, anti-Sm). Yes No Unknown		
Co	mplete the following section based on the patient's diagnosis, if applicable.		
	Is the patient currently receiving a stable standard treatment regimen for systemic lupus erythematosus (SLE) with any of the following (alone or in combination)? Glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone) Antimalarials (e.g., hydroxychloroquine) Immunosuppressives (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide) None of the above		

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Benlysta SGM - 11/2021.

Member Name: {{MEMFIRST}}} {{MEMLAST}}} DOB: {{ME	MBERDOB}} PA Number: {{PANUMBER}}		
Section B: Active Lupus Nephritis 9. Does the patient have clinically active lupus renal disease?	JYes □No		
10. Is the patient currently receiving a stable standard induction a	Is the patient currently receiving a stable standard induction and maintenance treatment for lupus nephritis (e.g cyclophosphamide, mycophenolate mofetil, azathioprine, glucocorticoids)?		
cyclophosphamiae, mycophenolaic molecn, azaumopime, grav	deconicolas). The test to		
I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.			
X	Date (mm/dd/sa)		
Frescriber of Authorized Signature	Date (mm/dd/yy)		

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Benlysta SGM - 11/2021.